BeOne Medicines (formerly BeiGene) Oncology Portfolio

Founded in 2010, the company formerly known as BeiGene underwent a significant transformation and rebranding to become BeOne Medicines AG. Originally established as a research-focused biotechnology firm in Beijing, China, the company has rapidly evolved into a global leader in the discovery and development of innovative oncology treatments, such as its flagship BTK inhibitor Brukinsa.

Starting in 2024 and culminating in 2025, the company officially redomiciled to Switzerland to reflect its international scope and neutral operating position. Today, BeOne Medicines maintains a massive global footprint with manufacturing facilities in the United States (including a major site in Hopewell, New Jersey) and China. Its ownership is publicly traded on the Nasdaq, representing a diverse group of international institutional investors and shareholders, marking its transition from a regional Chinese biotech firm to a truly global pharmaceutical powerhouse.